ZOETIS INC. - ZTS STOCK NEWS

Zoetis reported Q3 2022 revenue of $2.0 billion, a 1% increase year-over-year, with net income at $529 million or $1.13 per diluted share, reflecting decreases of 4% and 3%, respectively. Operational growth was strong, with a 5% revenue rise and 2% adjusted net income increase. The company has lowered its full-year revenue guidance to $8.000 - $8.075 billion due to supply constraints and foreign exchange impacts. Key product sales in the companion animal segment showed promise, though livestock product sales faced challenges.

Vyond has announced its Fall Release of Vyond Studio, enhancing enterprise video creation through AI integration. The new features enable businesses to produce videos up to 10X faster and 130% more engaging than traditional methods. Users can now import SVG files, utilize advanced charts, and access AI-powered tools such as Instant Video Translation into 71 languages. These updates aim to improve communication in HR, Sales, and Marketing, empowering companies like Zoetis to streamline onboarding and training initiatives.

Zoetis Inc. (NYSE:ZTS) has declared a $0.325 per share dividend for Q4 2022, payable on December 1, 2022, to shareholders on record as of November 1, 2022. With a revenue of $7.8 billion in 2021, Zoetis is a leader in animal health, driven by innovation in animal care over 70 years. Their portfolio includes medicines, vaccines, and diagnostics for animals worldwide. This dividend reflects the company's commitment to providing returns to investors while sustaining growth.

Zoetis has been awarded a spot on Fortune’s 2022 Change the World list, ranking 20th among 50 companies recognized for their positive social impact. This recognition stems from Zoetis’ African Livestock Productivity and Health Advancement (A.L.P.H.A.) initiative, which has significantly improved veterinary care access in Sub-Saharan Africa over the past five years. Key achievements include:

• 91 veterinary products available
• 128 million animals treated
• 16 operational diagnostic labs
• 26,000 trained individuals in veterinary care

Zoetis Inc. (NYSE: ZTS) has successfully completed the acquisition of Jurox, an Australian animal health company. This acquisition enhances Zoetis' product range, particularly with the addition of Alfaxan®, a leading anaesthetic for companion animals. The move is anticipated to provide greater global expansion opportunities and valuable insights into the Australian animal health market. Jurox's established operations, which include over 150 veterinary medicines, will contribute to Zoetis' growth in its fourth largest market based on revenue.

Zoetis Inc. (NYSE:ZTS) will host a conference call on Nov. 3, 2022, at 8:30 a.m. ET, to discuss its third quarter 2022 financial results. CEO Kristin Peck and CFO Wetteny Joseph will lead the discussion and answer questions from analysts. The public can access the live webcast through the Zoetis investor website. The company reported $7.8 billion in revenue for 2021 and operates in over 100 countries, showcasing its strong global presence in animal health.

For the ninth consecutive year, Zoetis has been recognized by Seramount as one of their 100 Best Companies, highlighting its commitment to family-friendly benefits and workplace flexibility. Additionally, A.J. Edge and Daniel Edge were honored as Working Parents of the Year. The company offers programs such as paid parental leave, childcare reimbursement, and mental health benefits to support its employees. These accolades emphasize Zoetis' dedication to inclusivity and employee well-being in its workplace culture.

Zoetis (NYSE: ZTS) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 2:05 p.m. ET. Wetteny Joseph, the Chief Financial Officer, will represent the company and answer analyst questions. A live audio webcast will be available at investor.zoetis.com, with a replay following the event. Zoetis, a leader in animal health, generated $7.8 billion in revenue in 2021 and operates in over 100 countries.

Zoetis reported second-quarter 2022 revenue of $2.1 billion, a 5% increase year-over-year. Net income reached $529 million, equating to $1.12 per diluted share, marking a 3% rise. Operationally, revenue grew 8% and adjusted net income rose 9%, excluding foreign currency impacts. The company updated its 2022 guidance, projecting revenue between $8.225 billion and $8.325 billion and diluted EPS of $4.65 to $4.75 on a reported basis.

Despite growth, Zoetis faces challenges including foreign exchange fluctuations and commodity competition.